Biote Corp Class A (BTMD) valuation
Biote P/E ratio history
Biote trades at 11.1 times its earnings over the last twelve months and 2.8 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 3.5 (year to Dec 2025) to 68.7 (year to Dec 2024), with a median of 38.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $2.60 | $0.74 | 3.5 | 5.6 |
| Dec 31, 2024 | $6.18 | $0.09 | 68.7 | — |
| Dec 31, 2023 | $4.94 | $0.13 | 38.0 | — |
| Dec 31, 2022 | $3.73 | — | n/m | 7.0 |
| Dec 31, 2021 | $9.80 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Biote valuation against its peers
| Company | Market value | P/E | Price / sales |
|---|---|---|---|
| BioteBTMD | $42.0M | 11.1 | 0.2 |
| Sanuwave HealthSNWV | $44.0M | 5.6 | 1.0 |
| Inmune BioINMB | $39.0M | — | — |
| CvrxCVRX | $37.0M | — | 0.6 |
| MyomoMYO | $48.0M | — | 1.1 |
| Aldeyra TherapeuticsALDX | $34.0M | — | — |
| Heron TherapeuticsHRTX | $53.0M | — | 0.4 |
| Aardvark TherapeuticsAARD | $30.0M | — | — |
| Gossamer BioGOSS | $30.0M | — | 0.6 |
| Peer median | 5.6 | 0.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: BTMD financials · BTMD returns
No forecast, no recommendation. This page describes Biote Corp Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.